Academic Journal
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
| Title: | Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB |
|---|---|
| Authors: | Renata de Sá Brito Fróes, Adriana Ribas Andrade, Mikaell Alexandre Gouvea Faria, Heitor Siffert Pereira de Souza, Rogério Serafim Parra, Cyrla Zaltman, Carlos Henrique Marques dos Santos, Mauro Bafutto, Abel Botelho Quaresma, Genoile Oliveira Santana, Rafael Luís Luporini, Sérgio Figueiredo de Lima Junior, Sender Jankiel Miszputen, Mardem Machado de Souza, Giedre Soares Prates Herrerias, Roberto Luiz Kaiser Junior, Catiane Rios do Nascimento, Omar Féres, Jaqueline Ribeiro de Barros, Ligia Yukie Sassaki, Rogerio Saad-Hossne |
| Source: | Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024) |
| Publisher Information: | Nature Portfolio, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Medicine LCC:Science |
| Subject Terms: | Inflammatory bowel disease, Registry, Epidemiology, Severity, Ulcerative colitis, Crohn’s disease, Medicine, Science |
| More Details: | Abstract The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) established a national registry of inflammatory bowel disease (IBD). The aim of the study was to identify clinical factors associated with disease severity in IBD patients in Brazil. A population-based risk model aimed at stratifying the severity of IBD based on previous hospitalization, use of biologics, and need for surgery for ulcerative colitis (UC) and Crohn’s Disease (CD) and on previous complications for CD. A total of 1179 patients (34.4 ± 14.7y; females 59%) were included: 46.6% with UC, 44.2% with CD, and 0.9% with unclassified IBD (IBD-U). The time from the beginning of the symptoms to diagnosis was 3.85y. In CD, 41.2% of patients presented with ileocolic disease, 32% inflammatory behavior, and 15.5% perianal disease. In UC, 46.3% presented with extensive colitis. Regarding treatment, 68.1%, 67%, and 47.6% received biological therapy, salicylates and immunosuppressors, respectively. Severe disease was associated with the presence of extensive colitis, EIM, male, comorbidities, and familial history of colorectal cancer in patients with UC. The presence of Montreal B2 and B3 behaviors, colonic location, and EIM were associated with CD severity. In conclusion, disease severity was associated with younger age, greater disease extent, and the presence of rheumatic EIM. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2045-2322 |
| Relation: | https://doaj.org/toc/2045-2322 |
| DOI: | 10.1038/s41598-024-54332-1 |
| Access URL: | https://doaj.org/article/961c99a6e38442c1a1d0f2bf4b6e8264 |
| Accession Number: | edsdoj.961c99a6e38442c1a1d0f2bf4b6e8264 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-024-54332-1 |
| Published in: | Scientific Reports |
| Language: | English |